Peptide reference
Selank
TP-7 ·Threonyl-Lysyl-Prolyl-Arginyl-Prolyl-Glycyl-Prolyl-Glutamic acid ·tuftsin analog Selank
What cited sources report about Selank
Selank (TP-7) is a synthetic heptapeptide of sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro-Glu, designed at the V.V. Zakusov Research Institute of Pharmacology in Moscow as a stabilized analog of the endogenous immunomodulatory peptide tuftsin. Selank is registered in Russia for generalized anxiety disorder, but has no FDA-approved indication and no marketing authorization in the United States, European Union, Canada, or Australia. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Doyno and White (2021) — Journal of Clinical Pharmacology
A 2021 review from the University of Connecticut School of Pharmacy grouped Selank with phenibut among “poorly studied Russian drugs with GABAergic mechanisms” being sold to U.S. consumers as dietary supplements outside of any FDA-approved drug pathway. The authors observed that meaningful evaluation of abuse potential should precede public access for compounds with central GABA-modulating activity.
Phenibut and selank are poorly studied Russian drugs with GABAergic mechanisms that are inexplicably sold to US consumers as dietary supplements.
Konstantinopolsky et al. (2022) — Bulletin of Experimental Biology and Medicine
A 2022 preclinical study from the V.V. Zakusov Research Institute of Pharmacology in Moscow observed reduced behavioral signs of naloxone-precipitated morphine withdrawal in rats receiving intranasal Selank. The authors framed the findings as preliminary support for further investigation of tuftsin-analog peptides in opioid-withdrawal models, and noted that the work was conducted by the same institution that originally synthesized the compound.
PubChem CID 11765600 — National Center for Biotechnology Information
The PubChem compound record catalogues Selank as a heptapeptide of sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro-Glu, molecular formula C33H57N11O11, molecular weight 783.9 g/mol. Aggregated synonyms include TP-7 and selanc; the record links to the supporting Russian pharmacological literature.
DrugBank DB16352
The DrugBank entry classifies Selank as an investigational tuftsin-analog peptide registered in Russia for anxiety, with no marketing authorization in the United States, European Union, Canada, or Australia. The record summarizes the proposed anxiolytic and immunomodulatory mechanisms drawn from the Russian-language literature.
Coverage notes
Most published Selank pharmacology originates from the V.V. Zakusov Research Institute and affiliated Russian groups; independent replication outside Russia is limited. No completed or active large-scale human trial of Selank is registered on ClinicalTrials.gov as of this writing.